Notícias

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Strong demand helps the Lilly-backed biotech raise nearly $129 million

The Danish drugmaker alleges Lilly's advertising misrepresents comparisons between rival obesity treatments.

Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic

Friday’s preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.

Novo Nordisk (NYSE:NVO) has asked a U. S.

Novo Nordisk said it asked a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive advertising to mislead consumers in a lawsuit. Friday’s preliminary injunction request, filed in the District of New Jersey, escalates legal proceedings initiated earlier this week. Novo has now asked the court to stop Eli Lilly from advertising its GLP-1 drugs while the lawsuit proceeds.

Eli Lilly is extending its push in neuroscience while the FDA wrestles with controversial peptide drugs.

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

There are plenty of reasons to love these companies.

Find insight on Roche Holding and Olympus in the latest Market Talks covering the health care sector.

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Two more Phase 3 trials showed weight loss above 20%

Retatrutide delivered substantial weight loss in two additional late-stage trials.

Drugmaker Eli Lilly said Thursday that it is on track to seek federal approval for its next-generation obesity drug early next year. Lilly became the first drug company to reach a trillion dollar valuation last fall as sales of its weight loss drugs took off. Among adults with general obesity, the weekly injectable lowered the weight of late-stage trial participants by an average of 28% over 80 weeks at the highest doses tested.

Investing.com -- Eli Lilly announced Thursday it will file for approval of its next-generation obesity drug retatrutide in the first quarter of 2027, pushing back from an earlier timeline that targeted this year. The pharmaceutical company said it needs additional time to collect and verify manufacturing and quality-control data required by regulators.

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...

If approved, Lilly’s triple-g agonist would become the company’s fifth glucagon-based drug to be marketed.

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

July 23 (Reuters) - India's Cipla reported a bigger-than-expected fall in first-quarter profit on Thursday, extending its run of declines on muted sales of a generic cancer drug and supply disruptions

Big Pharma is buying its way out of the patent cliff, while Novartis AG (NYSE:NVS) is trying to out-develop it. A Record Year for Biotech Deals The scale of that buying activity appears in this year’s deal totals. Biotech M&A has hit a record pace in 2026, with deal value reaching $216 billion so far […]

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the wrong direction for Novo. Here is what the stock reaction reveals about who is actually winning this war.

Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.